Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | PRKCA | P17252 | 5/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394036 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL9010956 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL10620809 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL8467738 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL7416016 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL3763399 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL9070261 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL9787451 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL10893167 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL14952939 | 0.94 | PRKCA (0.67) | MAPTMAPK1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12214079-B2 | Micronized lipids | MCAL THERAPEUTICS INC. (US) | 2025-02-04 | — | — | US | claimed |
| US-12214080-B2 | Micronized lipids | MCAL THERAPEUTICS INC. (US) | 2025-02-04 | — | — | US | claimed |
| CN-117580560-A | Micronised lipid | MCAL治疗公司 | 2024-02-20 | — | — | CN | claimed |
| US-20220362154-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2022-11-17 | — | — | US | claimed |
| US-20220362155-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2022-11-17 | — | — | US | claimed |
| US-20250221934-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250221933-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2025-07-10 | — | — | US | disclosed |
| US-12214080-B2 | Micronized lipids | MCAL THERAPEUTICS INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-12214079-B2 | Micronized lipids | MCAL THERAPEUTICS INC. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-117580560-A | Micronised lipid | MCAL治疗公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20220362154-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220362154-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220362155-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220362155-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2022-11-17 | — | — | US | disclosed |
| US-9994511-B2 | Method of treating ocular disorders with compounds found in Harderian gland secretions | RestorTears, LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160168073-A1 | METHOD OF TREATING OCULAR DISORDERS WITH COMPOUNDS FOUND IN HARDERIAN GLAND SECRETIONS | RestorTears, LLC | 2016-06-16 | — | — | US | disclosed |
| US-9289494-B2 | Method of treating ocular disorders with compounds found in Harderian gland secretions | RestorTears, LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150141509-A1 | METHOD OF TREATING OCULAR DISORDERS WITH COMPOUNDS FOUND IN HARDERIAN GLAND SECRETIONS | RestorTears, LLC | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362155-A1 | MICRONIZED LIPIDS | SGMS1, SGMS2, MGLL | MAPT 3140/4885MAPK1 2331/4885PRKCA 3445/4885 |
| US-20250221933-A1 | MICRONIZED LIPIDS | SGMS1, SGMS2, MGLL | MAPT 3140/4885MAPK1 2331/4885PRKCA 3445/4885 |
| US-20160168073-A1 | METHOD OF TREATING OCULAR DISORDERS WITH COMPOUNDS FOUND IN HARDERIAN GLAND SECRETIONS | PLA2G2D, PLA2G2C, PLA2G3 | MAPT 3372/4885MAPK1 3587/4885PRKCA 3038/4885 |
| US-20220362154-A1 | MICRONIZED LIPIDS | SGMS1, SGMS2, MGLL | MAPT 3140/4885MAPK1 2331/4885PRKCA 3445/4885 |
| US-20150141509-A1 | METHOD OF TREATING OCULAR DISORDERS WITH COMPOUNDS FOUND IN HARDERIAN GLAND SECRETIONS | PLA2G2D, PLA2G2C, PLA2G3 | MAPT 3372/4885MAPK1 3587/4885PRKCA 3038/4885 |
| US-20250221934-A1 | MICRONIZED LIPIDS | SGMS1, SGMS2, MGLL | MAPT 3140/4885MAPK1 2331/4885PRKCA 3445/4885 |
| US-12214079-B2 | Micronized lipids | SGMS1, SGMS2, MGLL | MAPT 3140/4885MAPK1 2331/4885PRKCA 3445/4885 |
| US-12214080-B2 | Micronized lipids | SGMS1, SGMS2, MGLL | MAPT 3140/4885MAPK1 2331/4885PRKCA 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.